Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019
October 11 2019 - 10:00AM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
biopharmaceutical company, today announced that three abstracts
highlighting clinical and nonclinical data for bardoxolone methyl
(bardoxolone) will be presented at the American Society of
Nephrology Kidney Week 2019 Annual Meeting being held from November
5 – 10, at the Walter E. Washington Convention Center in
Washington, D.C.
Abstracts selected for presentation are
summarized below and are available on the conference website at
https://www.asn-online.org/education/kidneyweek/archives/.
Title: Activation of the
Keap1/Nrf2 pathway increases GFR by increasing glomerular effective
filtration area without affecting the afferent/efferent arteriole
ratioPresenter: Kengo Kidokoro, M.D. Ph.D.,
Department of Nephrology and Hypertension, Kawasaki Medical School,
Kurashiki, Okayama, JapanASN Abstract #
3236277. Poster
TH-PO378: November 7, 2019 from 10:00 AM to
12:00 PM
Title: Effect of
Bardoxolone Methyl on Kidney Events in Patients with Chronic Kidney
Disease Stage 4 and Type 2 Diabetes at High Risk of Adverse Kidney
OutcomesPresenter: Christoph Wanner, M.D.,
Department of Medicine and Chief of the Division of Nephrology,
University of Würzburg, GermanyASN Abstract #
3235604. Poster Board
TH-PO444: November 7, 2019, 10:00 AM to
12:00 PM
Title: A Cardiovascular
Risk Mitigation Strategy on the Safety of Bardoxolone Methyl
Post-BEACONPresenter: Pablo E. Pergola,
M.D., M.Ph., Research Director, Renal Associates, PA, San Antonio,
TXASN Abstract # 3237383. Poster
Board SA-PO918: November 9, 2019
from 10:00 AM to 12:00 PM
About Bardoxolone
Bardoxolone is an experimental, oral, once-daily
activator of Nrf2, a transcription factor that induces molecular
pathways that promote restoration of mitochondrial function,
reduction of oxidative stress, and inhibition of pro-inflammatory
signaling. The FDA has granted orphan drug designation to
bardoxolone for the treatment of Alport syndrome, autosomal
dominant polycystic kidney disease, and pulmonary arterial
hypertension. The European Commission has granted orphan drug
designation to bardoxolone for the treatment of Alport
syndrome. Bardoxolone is currently being studied in CARDINAL,
a Phase 3 study for the treatment of Alport syndrome, FALCON, a
Phase 3 study for the treatment of ADPKD, CATALYST, a Phase 3 study
for the treatment of connective tissue disease-associated pulmonary
arterial hypertension, and AYAME, a Phase 3 study for the treatment
of diabetic kidney disease in Japan. AYAME is being conducted
by Reata’s licensee Kyowa Kirin Co., Ltd.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and
inflammation. Reata’s two most advanced clinical candidates,
bardoxolone and omaveloxolone, target the important transcription
factor Nrf2 that promotes restoration of mitochondrial function,
reduction of oxidative stress, and inhibition of pro-inflammatory
signaling. Bardoxolone and omaveloxolone are
investigational drugs, and their safety and efficacy have not been
established by any agency.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, and
our ability to obtain and retain regulatory approval of our product
candidates. You can identify forward-looking statements
because they contain words such as “believes,” “will,” “may,”
“aims,” “plans,” “model,” and “expects.” Forward-looking
statements are based on Reata’s current expectations and
assumptions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that may differ materially from those
contemplated by the forward-looking statements, which are neither
statements of historical fact nor guarantees or assurances of
future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to, (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) the potential market size and the size of the
patient populations for our product candidates, if approved for
commercial use, and the market opportunities for our product
candidates; and (iv) other factors set forth in Reata’s filings
with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K, under the caption “Risk Factors.”
The forward-looking statements speak only as of the date made and,
other than as required by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:Vinny JindalVice President,
Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Media:Matt Middleman, M.D.LifeSci Public
Relations(646)
627-8384matt.middleman@lifescipublicrelations.com
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024